Doer Biologics Attended the Conference of “Biopharma Development & Production 2018” in Shanghai
As one of VIP guests, CEO Dr. Yanshan Huang, together with other four CEO peers from different countries, shared their views on “Global and local biopharma market trends and implications” with audience at the opening plenary discussion. Dr. Huang highly praised the great achievement of china biopharma industry had made in the past decades. Meanwhile, Dr. Huang said the policy and regulation guidance issued by CFDA are also encouraging more and more investments and talents to devote themselves into the discovery of innovative drugs. He believes that it will be a golden time for the discovery of innovative drugs in next one or two decades in China.
Dr. Yang presented a speech of “A novel poly-agonist drug candidate for the comorbidity of obesity and Type II diabetes”, introducing our being-developed innovative drug candidate Dr10619.
The double burden of obesity and Type II diabetic mellitus make it a hard disease for cure. Most of anti-diabetic drugs in the market cannot reduce body weight while lowering blood sugar, which makes them are not suitable for the comorbidity of obesity and Type II diabetic mellitus. Dr10619 is a poly-agonist drug candidate for obesity and Type II diabetes. As a single molecule, it has well-balanced activities of GCG, GLP-1 and FGF21, which is based on the technology of Multibody® platform. Unlike anti-diabetic drugs in the market, Dr10619 has long administration frequency, around once a week, and potent efficacy on lowering blood glucose and reducing body weight. Meanwhile, Dr10619 also showed potent efficacy on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatoheptitis (NASH).
The innovative Dr10619 had greatly interested and inspired audience for the enthusiasm on innovative drugs. During the closing plenary discussion, Dr. Yang, as one of distinguished speakers, together with Dr. Yun Kang, vice president of Generon (Beijing), Dr. Alvin Luk, senior vice president of Shanghai Henlius Biotch, Dr. Junhua Qiao, Senior director of I-Mab Biopharma, had a great discussion and thought exchange with audience on the next decade of China’s biopharmaceutical industry.
IBC Asia is Singapore’s leading conference, exhibition and training company, with a 30-year history and a part of the Informa Group. Informa Group is a leading business intelligence, academic publishing, knowledge and events business, operating in the Knowledge and Information Economy. Informa is listed on the London Stock Exchange and a member of the FTSE 100. IBC develops high level and pioneering industry conferences that inspire, educate and drive business strategy, and provide targeted networking and business matching to create new partnership opportunities.